CERA: third-generation erythropoiesis-stimulating agent
Explore this paper's citation graph
Summary
CERA has a dramatically lengthened half-life, making it the only ESA licensed for once-a-month dosing, however, like the previous ESA, CERA has not been shown to reduce morbidity or mortality and has only been show to correct anemia and improve quality of life.
- Type
- article
- Published
- 2008-03-17
- Cited by
- 42
- References
- 56
- OpenAlex
- https://openalex.org/W18345959
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32385190
Keywords
Hydrocephalus, Categorical variable, Perspective (graphical), Congenital hydrocephalus, Medicine
References
- Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
- Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988-1994).
- Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology.
- Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells.
- Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple‐dose, phase II study
- Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
- European best practice guidelines for the management of anaemia in patients with chronic renal failure.
- Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open‐label, Australian study
- Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
- C.E.R.A. Maintains Stable Control of Hemoglobin in Patients with Chronic Kidney Disease on Dialysis when Administered Once Every Two Weeks
- Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin.
- Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
- Pharmacokinetic and Pharmacodynamic Properties of Methoxy Polyethylene Glycol‐Epoetin Beta Are Unaffected by the Site of Subcutaneous Administration 1
- Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding Assay
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
- Correction of anemia with epoetin alfa in chronic kidney disease.
- Prevalence of chronic kidney disease in the United States.
- Prevalence of decreased kidney function in Chinese adults aged 35 to 74 years.
- Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non‐Hodgkin’s lymphoma receiving combination chemotherapy
- Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy
Cited by
- Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC-MS/MS and western blotting: a comparative study.
- Population pharmacokinetic / pharmacodynamic analysis of erythropoiesis kinetics
- Cellular lifespan based pharmacodynamic analysis of erythropoiesis
- Optimization of anemia management in preterm infants
- Cell microencapsulation for therapeutic purposes: towards greater control over biocompatibility
- Therapeutic oligonucleotides with polyethylene glycol modifications.
- BiOsimilaRs in the management of anaemia secondary to chemotherapy in HaEmatology and Oncology: results of the ORHEO observational study
- Recombinant human erythropoietin therapy in predialysis patients of chronic kidney disease
- 말기신부전 환자에서 빈혈 및 영양관리
- Methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa for anemia in non-dialysis-dependent CKD: a systematic review
- Emerging technologies in the delivery of erythropoietin for therapeutics
- Current controversies in the management of the anemia of prematurity.
- Emerging drugs for treatment of anemia of chronic kidney disease
- Hormones as doping in sports
- The Waveform Fluctuation and the Clinical Factors of the Initial and Sustained Erythropoietic Response to Continuous Erythropoietin Receptor Activator in Hemodialysis Patients
- Emerging PEGylated drugs
- Erythropoietin use and abuse
- CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.
- Survival and proliferative roles of erythropoietin beyond the erythroid lineage
- Effect of Conversion from ESA with Shorter Half-Life to CERA Once Monthly for Maintaining Hb Concentration in Pre-Dialysis CKD Patients
Related papers
No related papers recorded.